Pfenex awarded third contract for development of novel anthrax vaccine

Pfenex, Inc., announced on Tuesday that it was awarded a contract as a subcontractor for Leidos Holdings, Inc., for the development of an anthrax vaccine using its recombinant protective antigen as a base.

The prime contract for the development of the vaccine was awarded to Leidos by the National Institute of Health's National Institute of Allergy and Infectious Diseases. The goal of the project is to develop a more effective vaccine against anthrax and the West Nile virus, building upon existing vaccines and technology.

Leidos and Pfenex will build upon existing vaccine technology by using a novel adjuvant to enhance the immune response. Pfenex will provide its rPA, which will be mixed with an adjuvant to create a broad range vaccine that produces a heightened autoimmune response against anthrax and West Nile virus.

This is the third government-funded contract received by Pfenex for the development of novel anthrax vaccines using its rPA technology, Pfenex Expression Technology.

"We are pleased to be awarded this contract as we expand our pipeline of rPA-based vaccine candidates in an effort to develop an optimal anthrax vaccine," Pfenex Chief Executive Officer Bertrand C. Liang said. "Pfenex Expression Technology has once again demonstrated its ability to efficiently produce high-value antigens and advance the development of next generation biodefense vaccines."

Organizations in this Story


Want to get notified whenever we write about Leidos ?
Next time we write about Leidos, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.